Article
Oncology
Santiago Sanchez-Sosa, Carlos Rodriguez-Medina, Ruth Stuckey, Yanira Florido, Guillermo Santana, Jesus Maria Gonzalez Martin, Naylen Cruz-Cruz, Melissa Torres-Ochando, Rosa Fernandez, Nuria Sanchez-Farias, Antonia Cionfrini, Teresa Molero Labarta, Maria Teresa Gomez-Casares, Cristina Bilbao-Sieyro
Summary: Recent advances in sequencing technologies and genomics have led to the development of targeted therapies for personalized treatment of acute myeloid leukemia (AML). However, the molecular profiles of patients who will respond to induction therapy and novel directed therapies are still unknown.
Review
Oncology
Eleonora Boscaro, Irene Urbino, Federica Maria Catania, Giulia Arrigo, Carolina Secreto, Matteo Olivi, Stefano D'Ardia, Chiara Frairia, Valentina Giai, Roberto Freilone, Dario Ferrero, Ernesta Audisio, Marco Cerrano
Summary: Several factors, including patient-related factors, AML manifestations at diagnosis, and disease genetics, are crucial in accurately estimating AML prognosis. However, the rapidly evolving field and the availability of MRD data have made traditional prognostic factors less reliable. This review summarizes established and new AML risk factors and discusses emerging comprehensive approaches to integrate relevant prognostic data.
Review
Oncology
Marisa J. L. Aitken, Farhad Ravandi, Keyur P. Patel, Nicholas J. Short
Summary: Quantification of measurable residual disease (MRD) provides critical prognostic information in acute myeloid leukemia (AML), with different detection platforms having varying sensitivity and applicability. MRD negativity is associated with reduced risk of relapse in AML, but the therapeutic implications remain unclear and require further investigation.
JOURNAL OF HEMATOLOGY & ONCOLOGY
(2021)
Review
Oncology
A. Bazinet, H. M. Kantarjian
Summary: Acute myeloid leukemia (AML) is a genetically heterogeneous disease. Personalized therapy based on patient characteristics and cytogenetic/molecular features is now possible. Intensive or low-intensity treatment approaches can be selected based on patient age and/or comorbidities. Molecularly defined AML subtypes benefit from targeted agents, while novel therapies are needed for TP53-mutated AML. Optimization of AML therapy in patients without actionable mutations and the role of measurable residual disease in modifying therapy are also discussed.
ANNALS OF ONCOLOGY
(2023)
Review
Oncology
Hilbeen Hisham Saifullah, Claire Marie Lucas
Summary: Chronic myeloid leukemia (CML) is a lifelong blood cancer treatment that can lead to side effects and impact quality of life for some patients. Clinical trials are investigating which patients can safely stop treatment in order to achieve treatment-free remission. Currently, there is limited understanding of the mechanisms behind treatment-free remission and identifying prognostic factors for successful discontinuation of treatment.
Article
Pediatrics
Jing Sun, Ru Zhang, Jianjun Tang, Xuedong Wu, Lu Zhu, Haiying Huang, Huimin Chen, Minhua Xiao, Hongfeng Luo, Haiqing Zheng, Jiaqi Chen
Summary: This study investigated the relationship between obesity and short-term outcomes in children with acute lymphoblastic leukemia (ALL). The results showed that obesity affects the outcome of ALL patients, with higher BMI being associated with increased minimal residual disease (MRD). In addition, higher BMI was also associated with increased leptin levels at diagnosis.
FRONTIERS IN PEDIATRICS
(2022)
Article
Medicine, General & Internal
Iram Shireen, Sumra Komal, Abida Mateen Ansari, Lubna Meraj
Summary: The objective of this study was to determine the frequency of complete remission rate in patients with Acute Myeloid Leukemia (AML) after standard 3+7 induction therapy among different clinicopathological groups. The study found that the complete remission rate in AML patients after 3+7 induction therapy was 54%, with better outcomes observed in younger age group, male patients, and those with lower LDH and TLC levels.
PAKISTAN JOURNAL OF MEDICAL SCIENCES
(2022)
Article
Multidisciplinary Sciences
Kwai Han Yoo, Hyeoung-Joon Kim, Yoo Hong Min, Dae-Sik Hong, Won Sik Lee, Hee-Je Kim, Ho-Jin Shin, Yong Park, Je-Hwan Lee, Hawk Kim
Summary: Age influences the biology and clinical outcomes of AML patients, with a decrease in the proportion of favorable risk patients and those receiving induction chemotherapy as age increases. The rates of achieving complete response (CR) also decrease with age, particularly in patients over 60 years old.
Review
Biophysics
Masamitsu Yanada
Summary: The longstanding debate regarding allogeneic HCT for AML patients in CR1 remains unsettled, but advancements in understanding disease molecular pathogenesis and transplantation practices are continuously evolving the indications for this treatment approach.
BONE MARROW TRANSPLANTATION
(2021)
Article
Oncology
Courtney D. DiNardo, Curtis A. Lachowiez, Koichi Takahashi, Sanam Loghavi, Lianchun Xiao, Tapan Kadia, Naval Daver, Maria Adeoti, Nicholas J. Short, Koji Sasaki, Sa Wang, Gautam Borthakur, Ghayas Issa, Abhishek Maiti, Yesid Alvarado, Naveen Pemmaraju, Guillermo Montalban Bravo, Lucia Masarova, Musa Yilmaz, Nitin Jain, Michael Andreeff, Elias Jabbour, Guillermo Garcia-Manero, Steven Kornblau, Farhad Ravandi, Marina Y. Konopleva, Hagop M. Kantarjian
Summary: The combination of fludarabine, cytarabine, granulocyte colony-stimulating factor, and idarubicin with venetoclax showed to be an effective treatment regimen in both newly diagnosed and relapsed or refractory AML patients, resulting in deep remissions and high rates of successful transplantation.
JOURNAL OF CLINICAL ONCOLOGY
(2021)
Article
Immunology
Guan-hua Hu, Yi-fei Cheng, Ying-xi Zuo, Ying-jun Chang, Pan Suo, Jun Wu, Yue-ping Jia, Ai-dong Lu, Ying-chun Li, Yu Wang, Shun-chang Jiao, Long-ji Zhang, Xiang-yu Zhao, Chen-hua Yan, Lan-ping Xu, Xiao-hui Zhang, Kai-yan Liu, Le-ping Zhang, Xiao-jun Huang
Summary: This study demonstrates that CAR-T therapy can effectively eliminate MRD and improve survival in patients with suboptimal MRD response.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Hematology
Jana Ihlow, Sophia Gross, Leonie Busack, Anne Floercken, Julia Jesse, Michaela Schwarz, Nina Rosa Neuendorff, Ann-Christin Von Bruenneck, Ioannis Anagnostopoulos, Seval Tuerkmen, Igor Wolfgang Blau, Thomas Burmeister, David Horst, Lars Bullinger, Joerg Westermann
Summary: This retrospective study analyzed the prognostic impact of early bone marrow assessment in 1,008 newly diagnosed acute myeloid leukemia patients. It found that early blast persistence had a negative prognostic impact on overall survival, event-free survival, and relapse-free survival. However, patients who achieved at least partial remission and subsequent blast clearance showed improved outcomes. The study suggests that the time slope of remission can inform post-induction therapy decision-making.
Article
Genetics & Heredity
Fangshu Liu, Suqi Deng, Yue Li, Juan Du, Hui Zeng
Summary: In this study, the researchers found that the high expression level of SLC25A1 gene in AML patients is associated with unfavorable prognosis. They further demonstrated that inhibition of SLC25A1 can inhibit the proliferation and increase the apoptosis of AML cells. By constructing a SLC25A1-associated gene panel, they established a prognostic risk-scoring model that can be used as an independent biomarker to assess prognosis in AML.
FRONTIERS IN GENETICS
(2023)
Article
Health Care Sciences & Services
Maria A. Kolesnikova, Aleksandra V. Sen'kova, Tatiana I. Pospelova, Marina A. Zenkova
Summary: Acute myeloid leukemia (AML) is a hematopoietic disorder with extremely short survival. The response to therapy and overall survival in AML patients is influenced by various patient- and tumor-associated factors, including tumor cell resistance to chemotherapeutic agents. In this study, a new prognostic scale based on multiple factors was developed to stratify AML patients and predict their treatment response and survival outcomes.
JOURNAL OF PERSONALIZED MEDICINE
(2023)
Article
Oncology
Megan Othus, Guillermo Garcia-Manero, John Godwin, James Weick, Derek Stirewalt, Frederick Appelbaum, Harry Erba, Elihu Estey
Summary: In a study of 1247 AML patients over four decades, the decade of therapy was found to be the most important factor affecting long-term survival, while achieving CR within 100 days was the second most important variable. Additionally, the protocol/decade of therapy was identified as a significant predictor of survival at year 2 or 3.
LEUKEMIA & LYMPHOMA
(2021)